The Company will issue a release after the oral presentation that will include the 5-year OS data, which is the longest OS ...

Immatics N.V. remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a robust cell therapy pipeline.

One treatment-related death occurred in the combination therapy group.

The human eye is often described metaphorically as the "window to the soul," but in clinical medicine, it is more accurately viewed as a non-invasive window into the human body's circulatory and ...

Adding the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab to percutaneous hepatic perfusion may improve survival outcomes in patients with ...

The ORR was 28.2% for younger patients and 30.4% for older patients, and the DCR was 43.9% and 48.8%, respectively. Older melanoma patients receive fewer treatment lines and different treatment ...

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

Percutaneous hepatic perfusion plus ipilimumab/nivolumab improved 1-year PFS to 54.7% versus 15.8% with hepatic perfusion alone (adjusted HR, 0.34), with median PFS 12.8 versus 8.3 months. Response ...

Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication ...

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; ...